 |
|
|
| |
Projected Health and Economic Impact of Hepatitis C on the
United States Veterans Administration Health System From 2014 To 2024
|
| |
| |
Reported by Jules Levin
DDW 2014 May 4-6 Chicago, ILL
David B. Rein1, John S. Wittenborn1, Danielle K. Liffmann1, Joshua M. Borton1, Jennifer C. Hasche1, Jennifer R. Kramer2, Zhigang Duan2, Hashem El-Serag2
1. NORC at the University of Chicago
2. Houston VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center
"the prevalence of cirrhosis among patients with HCV increased from 9.6% in 1996 to 18.5% in 2006. The prevalence of decompensated cirrhosis and hepatocellular carcinoma also increased dramatically over those years, from 5% to 11% and from 0.07% to 1.3% respectively.[4]......novel all-oral treatment regimens expected to be available in 2014 (AOR)......In 2014, 2019, and 2024, deaths would decrease by 10.9%, 12.3%, and 13.7% with PRPI, and by 50.2%, 56.7%, and 63.1% with AOR......There are a substantial number of people in the VA system living with Hepatitis C Virus....... This number is declining as the population with Hepatitis C ages and dies from Hepatitis C and other causes...... We are currently analyzing the VA data with the intent of estimating the annual health costs of individuals per stage of disease progression with stages defined as chronic hepatitis C, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplant and post transplant stages, and death within a year diagnosed with HCV. We will estimate econometric health expenditure models to determine the cost per stage per patient per year"
|
| |
|
|
|
|
|
